Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

28.55 -0.51 (-1.75%)

Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

November 04, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

October 20, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 02, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

August 06, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

June 26, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 27, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 06, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 05, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 05, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

May 05, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

March 30, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 08, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Prepares for Transformational 2026

January 06, 2026

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

December 22, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

November 03, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

October 21, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Proposed Underwritten Public Offering

October 21, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

October 20, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

September 15, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

August 06, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 04, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

July 30, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 03, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2025

From Viridian Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.